

General Information

Venue, Travel and Accommodation

Babraham Campus, Babraham Hall, Babraham, Cambridgeshire CB22 3AT. The venue is easily accessible from the M11 and A11, and there is ample on-site parking. A bus will leave from Whittlesford Parkway railway station for the start of the conference and will return to the station at the close of the event. A list of suggested accommodation options may be found on the event website, and the conference is offering free-of-charge transport between two of the hotels and the venue (subject to availability).

Organising Committee

Kevin Doyle	(BioFocus)
Roger Griffin	(Newcastle University)
John Harris	(CJH Consultants)
Keith Jones	(Institute of Cancer Research and SCI)
Jackie Macritchie	(BioFocus and RSC) - chairman
Sarah Rook	(Evotec and SCI)
Andrew Thomas	(AstraZeneca)

Sponsorship and Exhibition

Exhibition spaces are very limited and the charge includes one full delegate attendance, with drinks reception and conference barbecue.

Sponsors are encouraged - please contact the secretariat for information about exhibition and sponsorship opportunities.



WORLDWIDE RESEARCH & DEVELOPMENT
Medicinal Chemistry




Contact/Secretariat

Mrs Maggi Churchouse, 3 East Barn, Market Weston Road,
Thelnetham, DISS, Suffolk IP22 1JJ, UK
Telephone and fax: +44 (0)1359 221004
E-mail: maggi@maggichurchousevents.co.uk

Website Address

www.maggichurchousevents.co.uk/bmcs
www.rsc.org/bmcs

Second Announcement and Call for Posters




Kinase 2014:

Past, Present and Beyond

6th RSC / SCI symposium on kinase inhibitor design

Monday-Tuesday, 19th-20th May 2014

Babraham Research Campus, Cambridge, UK



Introduction and Programme

Synopsis

Now with over 20 FDA approved small molecules, the field of kinase inhibition has matured. The sixth RSC/SCI symposium on kinases will encompass case studies of on-going programmes as well as successful past kinase programmes, with examples from the CNS, inflammation/respiratory and oncology fields. The question of emerging resistance to kinase inhibitors will be raised along with techniques being developed to address this. The symposium will include perspectives and discussions on the future of kinase inhibitor research.

Who should attend?

This event is aimed at all scientists interested in furthering their knowledge of kinases. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry.

Programme

Monday, 19th May

09:00 Registration

10:00 Opening remarks

Session Chair: John Harris, CJH Consultants (UK)

10:10 **Clinical experience with kinase inhibitors for the treatment of cancer**

Andrew Mortlock, AstraZeneca (UK)

10:50 **The discovery and optimisation of a series of potent, selective and CNS restricted pan-Trk ligands for pain**

Sharan Bagal, Pfizer Neusentis (UK)

11:30 **Chemoproteomic applications in kinase drug discovery**

Douglas Thomson, Cellzome (Germany)

12:10 *Lunch*

Session Chair: Keith Jones, Institute of Cancer Research (UK)

13:10 **Fragment-based discovery of selective inhibitors of maternal embryonic leucine zipper kinase**

Chris Johnson, Astex Pharmaceuticals (UK)

13:50 **Brain penetrant PI3K inhibitors for the treatment of glioblastoma: optimisation of free brain concentrations using an MPO approach**

Robert Heald, Argenta (UK)

14:30 **Inhalation by design: the discovery of slow-offset Janus Kinase (JAK) inhibitors towards the treatment of respiratory diseases**

Ian Storer, Pfizer (UK)

15:10 *Refreshments*

15:40 **Non-ATP site-directed kinase inhibitors**

Andreas Marzinzik, Novartis (Switzerland)

16:20 RSC / CPA (Royal Society of Chemistry / Chinese Pharmaceutical Association) session at Kinase 2014

17:25 *Drinks reception and poster session followed by conference barbecue*

Tuesday, 20th May

Session Chair: Roger Griffin, Newcastle University (UK)

09:00 **Acquired resistance to kinase inhibitors – the problem and some solutions**

Simon Cook, The Babraham Institute (UK)

09:40 **The resurgence of covalent drugs**

Russell Petter, Celgene (USA)

10:20 *Refreshments*

10:50 **The discovery of AZD9291: a mutant selective, third generation EGFR inhibitor**

Ray Finlay, AstraZeneca (UK)

11:30 **Discovery and characterisation of potent and selective inhibitors of ATR kinase as anti-cancer agents**

John Pollard, Vertex Pharmaceuticals (UK)

12:10 *Lunch*

Session Chair: Andrew Thomas, AstraZeneca (UK)

13:10 **LY2835219. A CDK4/6 dual inhibitor with unique pharmacology and physicochemical properties**

Concepcion Sanchez-Martinez, Lilly (Spain)

13:50 *Interactive session*

14:30 **Targeting oncogenic kinases and K-RAS with covalent inhibitors**

Nathanael Gray, Dana-Farber Cancer Institute Harvard Medical School (USA)

15:10 *Closing remarks*

Call for Posters

A poster session will take place at the end of Day 1. A one-page abstract should be submitted to the Secretariat by 31st March 2014 using the template on the event website. When submitting posters, delegates should indicate whether they would be prepared to give a single-slide summary of their poster in a formal presentation session that will take place on the first day.

Registration Fees

Up until 31st March
£240 RSC and SCI members
£290 Non-members

From 1st April (applies to payments received after 31st March)
£280 RSC and SCI members
£330 Non-members

Students and Bursaries

£125 RSC and SCI student members* - flat rate
£150 Student non-member* - flat rate

* Student is undergraduate or post-graduate student, but not post-doctoral student. Some student bursaries will be available. Please contact the secretariat.

Exhibitors

£550 Exhibition stand with one full delegate attendance - flat rate

